New Zealand markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.70+0.06 (+0.90%)
At close: 04:00PM EDT
6.68 -0.02 (-0.30%)
After hours: 06:38PM EDT

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees218

Key executives

NameTitlePayExercisedYear born
Mr. Sheldon L. KoenigPres, CEO & Director728.91kN/A1966
Dr. Joanne Micale Foody FACC, M.D.Chief Medical Officer471.86kN/A1965
Dr. Kenneth J. FiorelliChief Technical Operations OfficerN/AN/AN/A
Mr. Benjamin ChurchHead of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Benjamin O. LookerGen. Counsel & Corp. Sec.N/AN/A1982
Mr. Keith F. LendenVP of Corp. Devel. & StrategyN/AN/A1973
Ms. Betty Jean SwartzChief Strategy OfficerN/AN/AN/A
Mr. Eric J. Warren R.Ph.Chief Commercial OfficerN/AN/A1973
Ms. April SeilerSr. Director of Project ManagementN/AN/AN/A
Roberta PetersonSr. Director of National AccountsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate governance

Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.